Dominantly Inherited Alzheimer Network

Dominantly Inherited Alzheimer Network
Name	Dominantly Inherited Alzheimer Network
Abbreviation	DIAN
Founded	2008
Founder	Reisa Sperling, Randall J. Bateman
Location	St. Louis, Missouri, United States
Mission	Research on autosomal dominant Alzheimer's disease

Dominantly Inherited Alzheimer Network is an international research consortium studying autosomal dominant Alzheimer's disease through longitudinal observational studies and biomarker development. The network brings together investigators, clinical centers, families, and pharmaceutical partners to map the preclinical trajectory of neurodegeneration linked to pathogenic mutations. It informs trial design, biomarker validation, and therapeutic strategies by integrating imaging, fluid biomarkers, genetics, and cognitive assessment.

Overview

The consortium unites academic centers such as Washington University in St. Louis, Massachusetts General Hospital, University of California, San Francisco, King’s College London, and McGill University with participants from families carrying mutations identified by groups including John Hardy and Rudolph Tanzi. Core activities incorporate modalities developed in labs associated with Roger N. Rosenberg, Dennis Selkoe, Barton W. Palmer, and Brad Hyman to track amyloid, tau, neurodegeneration, and cognitive decline observed in cohorts studied by teams like David M. Holtzman, Kaj Blennow, and Henrik Zetterberg. The program interacts with regulators and funders such as National Institutes of Health, Alzheimer's Association (US), and European Commission initiatives.

History and Organization

Launched in 2008 under leadership including Reisa Sperling and Randall J. Bateman, the consortium grew from single-center studies by investigators like Michael F. Egan and John C. Morris into a multicenter network modeled after consortia such as Alzheimer's Disease Neuroimaging Initiative and influenced by work from Stanley Prusiner and Paul Aisen. Governance includes steering committees with representatives from Harvard Medical School, University of Cambridge, Columbia University, and industry partners such as Eli Lilly and Company, Pfizer, and Roche. Data coordination centers at institutions like Washington University in St. Louis and platforms maintained by teams associated with Michael Weiner oversee harmonization, quality control, and protocol standardization across sites including University College London and University of Pittsburgh.

Research Aims and Study Design

Primary aims mirror objectives pursued by researchers including Reisa Sperling, Randall J. Bateman, Anne M. Fagan, and Carlos Cruchaga: to characterize biomarker trajectories, define clinical milestones, and accelerate preventive trials. The longitudinal design employs serial Positron emission tomography tracers pioneered in studies by William E. Klunk and Chao Han, magnetic resonance imaging protocols used by Bruce R. Rosen, cerebrospinal fluid assays refined by Kaj Blennow and Henrik Zetterberg, and plasma biomarkers developed in groups led by Oskar Hansson and David L. Morgan. Cognitive batteries draw on instruments validated at Alzheimer's Disease Research Center sites directed by John C. Morris and Nora Mattek.

Key Findings and Contributions

The network provided seminal evidence for preclinical biomarker cascades originally theorized in work by Rudolph Tanzi and Dennis Selkoe, documenting amyloid accumulation before tau spread and neurodegeneration, corroborating models advanced by B. R. Hyman and Reisa Sperling. DIAN data underpinned validation of PET ligands such as those from William E. Klunk and CSF analytes explored by Kaj Blennow, and supported plasma biomarker advances reported by Henrik Zetterberg and Oskar Hansson. Findings influenced trial endpoints used in studies led by Eric Reiman, Paul Aisen, and Rachelle Doody, and shaped regulatory discussions with agencies like U.S. Food and Drug Administration and European Medicines Agency.

Participant Recruitment and Ethical Considerations

Recruitment strategies engaged families affected by mutations discovered in genes studied by Christian Haass (presenilin), Michael Goedert (tau), and Peter St. George-Hyslop (APP), leveraging patient advocacy groups such as Alzheimer's Association (US), Alzheimer Society (Canada), and ALZ UK. Ethical frameworks reflect guidance from bioethicists linked to Hastings Center, Georgetown University, and University of Oxford and address issues raised in work by Pauline Boss and Tom Bashford. Consent, genetic counseling, disclosure policies, and psychosocial support parallel approaches used in multigenerational studies by Mary-Claire King and Francis Collins while safeguarding privacy consistent with principles endorsed by National Institutes of Health and institutional review boards at Harvard Medical School.

Collaborations and Data Sharing

The consortium shares de-identified data with platforms and initiatives including Alzheimer's Disease Neuroimaging Initiative, Global Alzheimer's Platform, and repositories curated by National Institute on Aging. Collaborative partnerships involve academic investigators such as Michael Weiner, Bradley Hyman, and John C. Morris as well as industry teams from Biogen and Genentech. Data harmonization efforts reference standards from Clinical Data Interchange Standards Consortium and leverage computational contributions from groups at Carnegie Mellon University, Massachusetts Institute of Technology, and University of Toronto.

Impact on Clinical Trials and Therapeutics

Insights from the network informed trial designs exemplified by trials run by Aducanumab-associated teams at Biogen, prevention trials conceptualized by Eric Reiman and Paul Aisen, and biomarker-guided programs at Eli Lilly and Company and Roche. The consortium's natural history models underpin adaptive trial methodologies advocated by statisticians at Johns Hopkins University and trial networks coordinated by Global Alzheimer Platform Foundation. Its contributions have influenced therapeutic strategies pursued by investigators such as Dennis Selkoe, John Hardy, and David M. Holtzman in pursuit of anti-amyloid and anti-tau approaches.

Category:Alzheimer's disease research